TD-HX959016

Belantamab(TD-HX959016) is a research-grade recombinant antibody targetingCD269. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.

Human

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Humanized

IgG1-kappa

Monoclonal

Tumor necrosis factor receptor superfamily member 17, TNFRSF17, CD269, B-cell maturation protein, BCMA, BCM

Please contact the lab for this information.

>95% purity as determined by SDS-PAGE.

Protein A/G purified from cell culture supernatant.

Q02223

Liquid

0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

BCMA, 2857916, GSK2857916, J6M0, J6M0-mcMMAF, 2061894-48-0

Belantamab mafodotin also known as GSK2857916 is a humanized, IgG1 antibody-drug conjugate (ADC) that binds specifically to BCMA. The parent anti-BCMA antibody (GSK2857914) is produced in an afucosylated form and is conjugated to the microtubule polymerization inhibitor MMAF, via a protease-resistant maleimidocaproyl (mc) linker, to produce the GSK2857916 ADC molecule. Upon binding to the cell surface, GSK2857916 is rapidly internalized and active cytotoxic drug (cys-mcMMAF) is released inside the cell causing cell-cycle arrest and apoptosis. Furthermore, the afucosylation of GSK2857916 leads to enhanced binding to FcγRIIIa receptors on the surface of immune effector cells, recruitment of immune cells, and antibody-dependent cellular cytotoxicity and phagocytosis (ADCC and ADCP, respectively). This dual mechanism of action enables improved efficacy by targeting both dividing (via ADC) and non-dividing (via ADCC/ADCP) tumor cells. Recently, belantamab mafodotin was approved under the name BLENREP in the United States and European Union for the treatment of patients with relapsed or refractory multiple myeloma.

SEC-HPLC detection for Research Grade Belantamab.　　|　Detects CD269/TNFRSF17/BCMA in indirect ELISAs.　　|　SDS-PAGE for Research Grade Belantamab.　　|　Flow-cytometry using anti-human CD269 antibody. Untransfected cells (blue Histogram) and Transfected cells (Yellow Histogram) were stained with an anti-human CD269 monoclonal antibody (Catalog: HX959016) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a Goat Anti-Human IgG H&L Polyclonal Antibody, FITC (abinScience: HF690414) and cells analysed on a NovoCyte Flow Cytometer.　　|　Western blot analysis was performed using anti-CD269 monoclonal antibody at 1ug/mL on various samples.Lane 1:recombinant human CD269 (Catalog No:TD-HX959011)Lane 2:negative control

For research use only. Not suitable for clinical or therapeutic use.